The Company confirms that it will release 2.5 year overall survival data from Phase 2b clinical trial OST-HER2 in the ...

The SMAB will assist the Company in engaging with the US Food & Drug Administration (FDA) regarding the safety and efficacy of its lead immunotherapy product candidate, OST-HER2, for the treatment of ...

Osteosarcoma is the most common primary bone cancer in children, adolescents, and young adults. Although chemotherapy and surgery have improved survival for localized disease, outcomes remain poor ...

Although advances have been made in both surgical and medical management of patients with osteosarcoma, the overall survival of patients with osteosarcoma has remained constant, with no substantial ...

Osteosarcoma is a malignant neoplasm of the bone and is the most common histological form of primary bone cancer. It is most prevalent in children and young adults, as it is associated with the ...

A recent clinical case has identified an unprecedented dual malignancy in the mandible, where multiple myeloma (MM) and ...

Dual RPDD and ODD for FL118 in osteosarcoma create regulatory incentives that may accelerate development for a rare, aggressive pediatric/AYA bone cancer with limited recurrent-disease options. FL118 ...

Osteosarcoma is the bone tumor that most commonly affects children, adolescents, and young adults. Before 1970, treatment primarily included surgical resection. However, the introduction of ...

While genetic sequencing has previously helped to uncover different subtypes of other cancers, like breast or skin cancer, for which those patients then receive targeted treatment personalised to ...

Comprehensive profiling of tumor samples taken from patients with osteosarcoma shows that multiple factors contribute to the traditionally poor responses observed from treatment with immune checkpoint ...